Methods blog · Cancer Systems Biology & Drug Resistance

Cross-talk perturbation map

How pancreatic cancer cells escape dasatinib: a signalling cross-talk network analysis

Coupling each gene's degree of dysregulation with the cross-talk between enriched pathways shows p53 and FcεRI signalling orchestrating 87% of the perturbation map in dasatinib resistance, and nominates BCL2L1 as a target.

#acquired drug resistance#pancreatic cancer#dasatinib#pathway cross-talk#TCGA#CPTAC#biomarkers

Acquired dasatinib resistance (ADR) undermines treatment of pancreatic cancer (PC). Prolonged exposure to the drug drives dynamic reprogramming of signalling, so the question is not only which genes change, but how the change spreads through interconnected pathways. This preprint (bioRxiv, 2026), with Muhammad J. A. Shiddiky and Mohammad Ali Moni, introduces a cross-talk network model to map that spread.

Data

Microarray profiles (Illumina HT-12 v4, GEO GSE59357) of three dasatinib-sensitive lines (Panc0504, Panc0403, Panc1005) and three dasatinib-resistant lines (MiaPaCa2, Panc1, SU8686), each with three biological replicates.

The pipeline

  1. Differential expression (limma with empirical Bayes): genes with \(|\log_2 \mathrm{FC}| \ge 1\) and FDR \(\le 0.05\) are called DEGs.
  2. Pathway enrichment and perturbation with SPIA, which combines two kinds of evidence: over-representation of DEGs (a hypergeometric \(p_{\mathrm{NDE}}\)) and the perturbation that DEGs propagate through the pathway’s signalling links. The total net accumulated perturbation of a pathway is \(t_A = \sum_i \mathrm{Acc}(g_i)\), and its significance is assessed against bootstrap randomisations of both topology and fold-changes, \(p_{\mathrm{PERT}} = \Pr(T_A \ge t_A \mid H_0)\).
  3. Signalling cross-talk network. DEGs from the enriched pathways are linked to the pathways they belong to. A cross-talking DEG is one that connects at least two pathways. The network is filtered to strongly dysregulated nodes (\(|\log_2 \mathrm{FC}| \ge 2\)) and pruned of degree-1 nodes.
  4. Hub prioritisation. Resistance biomarkers are the hubs with both high connectivity (the number of pathways cross-talking through the gene) and high dysregulation (\(|\log_2 \mathrm{FC}|\)). Correlation and Kolmogorov–Smirnov tests then characterise how hubs differ from the remaining genes.

The intuition: a gene that is strongly perturbed and bridges many pathways is well placed to disseminate the perturbation, acting as a hub or bottleneck that spreads resistance-associated signalling.

What we found

87%of the global perturbation map orchestrated by two pathways
10key resistance biomarkers
3independent validation layers (TCGA, CPTAC, STRING)
  • p53 signalling and Fc epsilon RI (FcεRI) signalling showed significant perturbation enrichment and, working complementarily, accounted for 87% of the global perturbation map in dasatinib resistance.
  • Statistical characterisation of the cross-talk network identified 10 key resistance biomarkers, including THBS1, CDKN1A and BCL2L1 within p53 signalling and RAC2 and MAPK13 within FcεRI signalling.
  • Validation against TCGA transcriptomics, CPTAC relative proteomics and STRING protein–protein interactions for prognostic potential singled out BCL2L1 as pivotal for spreading the global perturbation.

Why BCL2L1?

BCL2L1 encodes BCL-xL, an anti-apoptotic protein. Its position at the junction of the perturbed pathways makes it both a mechanistic explanation for survival under dasatinib and a therapeutic hypothesis: co-targeting BCL-xL (for example with BH3 mimetics) could re-sensitise resistant tumours. That is a hypothesis for experimental follow-up.

Lineage

This study extends the cross-talk modelling we developed for lapatinib resistance in breast cancer to a new drug and cancer type, and adds proteomic and clinical-cohort validation.

Read the paper

  1. Global dissemination of FC-epsilon RI and p53 signalling perturbation contribute to Dasatinib resistance in Pancreatic Cancer Cell-lines

    AKM Azad, Muhammad J. A. Shiddiky, Mohammad Ali Moni

    bioRxiv 2026.02.22.707324 · 2026

    PreprintFirst author OA

BibTeX